Tipranavir

Sold as Aptivus. Every FDA application for this active ingredient.

As of Nov 13, 2026, FDA lists 3 applications for Tipranavir (sold as Aptivus), first approved Jun 22, 2005, with 2 new uses approved and 0 published complete response letters.

First approved: Jun 22, 2005
Applications: 3
New uses approved: 2
Complete response letters: 0
Medicare spending, 2025: $850K

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Aptivus	Part D	$850K	-19%	45

Clinical Trials

1 open or ongoing study names this ingredient as an intervention, including as a comparator; newest first. See all

Study	Phase	Status	Posted
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)HIV-1-infection · Gilead Sciences	Phase 2 / Phase 3	Active, not recruiting	Aug 16, 2022

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Jun 22, 2005	AptivusNDA 21814 · New molecular entity	Boehringer Ingelheim	16	Marketed
Jun 23, 2008	AptivusNDA 21822 · New indication	Boehringer Ingelheim	0	Marketed
Jun 23, 2008	AptivusNDA 22292 · New dosage form	Boehringer Ingelheim	10	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA